GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Fulgent Genetics Inc (STU:7F0) » Definitions » Total Liabilities

Fulgent Genetics (STU:7F0) Total Liabilities : €86.7 Mil (As of Dec. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Fulgent Genetics Total Liabilities?

Fulgent Genetics's Total Liabilities for the quarter that ended in Dec. 2024 was €86.7 Mil.

Fulgent Genetics's quarterly Total Liabilities declined from Jun. 2024 (€96.05 Mil) to Sep. 2024 (€89.08 Mil) and declined from Sep. 2024 (€89.08 Mil) to Dec. 2024 (€86.72 Mil).

Fulgent Genetics's annual Total Liabilities declined from Dec. 2022 (€109.67 Mil) to Dec. 2023 (€93.57 Mil) and declined from Dec. 2023 (€93.57 Mil) to Dec. 2024 (€86.72 Mil).


Fulgent Genetics Total Liabilities Historical Data

The historical data trend for Fulgent Genetics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fulgent Genetics Total Liabilities Chart

Fulgent Genetics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 107.74 99.86 109.67 93.57 86.72

Fulgent Genetics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 93.57 94.98 96.05 89.08 86.72

Fulgent Genetics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Fulgent Genetics's Total Liabilities for the fiscal year that ended in Dec. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=69.619+(6.315+4.702
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+6.083+0)
=86.7

Total Liabilities=Total Assets (A: Dec. 2024 )-Total Equity (A: Dec. 2024 )
=1165.066-1078.347
=86.7

Fulgent Genetics's Total Liabilities for the quarter that ended in Dec. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=69.619+(6.315+4.702
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+6.083+0)
=86.7

Total Liabilities=Total Assets (Q: Dec. 2024 )-Total Equity (Q: Dec. 2024 )
=1165.066-1078.347
=86.7

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Fulgent Genetics Total Liabilities Related Terms

Thank you for viewing the detailed overview of Fulgent Genetics's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Fulgent Genetics Business Description

Traded in Other Exchanges
Address
4399 Santa Anita Avenue, El Monte, CA, USA, 91731
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.

Fulgent Genetics Headlines

No Headlines